Federal Circuit: Provisional Application Must Support Later Claims
The Federal Circuit in Enanta Pharmaceuticals v. Pfizer (June 23, 2026) affirmed that Pfizer’s Paxlovid-related U.S. Patent No. 11,358,953 cannot claim the provisional application’s July 20, 2020 priority because the provisional lacked written-description support for later claims. The court said changing alkyl range C2 to C1 was not supported, making Pfizer’s nirmatrelvir disclosure prior art and invalidating the asserted claims.
How this was made
The 30-second read
Why it matters
The Federal Circuit’s key holding is that disclosing C2-C12 alkyl does not support claiming C1-C12 alkyl, so the patent cannot use the provisional priority date. That makes Pfizer’s intervening public disclosure of nirmatrelvir prior art and invalidates the asserted claims.
Market read
A US appellate court decision directly affects the validity of a specific patent asserted in a Paxlovid-related infringement dispute, changing litigation risk for both ENTA and PFE.
What to watch
The article does not quantify damages, remaining patents, or whether Enanta can appeal further, so trading impact may be smaller or larger depending on the broader patent portfolio and case status.
Background
The dispute centers on whether a non-provisional patent can claim the earlier priority date of a provisional application when the provisional allegedly lacks written-description support for a later-claimed chemical substituent range.
Ticker impact
Federal Circuit affirmed that Enanta’s asserted ’953 patent claims fail to get provisional priority due to inadequate written description support.
Potentially negative bias for ENTA’s IP-driven litigation outlook; magnitude uncertain without market reaction data.
The decision removes earlier priority, making Pfizer’s intervening disclosure prior art and invalidating the asserted claims, which is directly adverse to Enanta’s infringement case.
Federal Circuit held Pfizer’s intervening disclosure of nirmatrelvir constitutes prior art because the ’953 patent lacked provisional priority.
Likely modest positive for PFE’s litigation risk profile; direct price impact uncertain absent stock-move context.
By denying priority, the court effectively validates Pfizer’s prior-art argument against Enanta’s infringement claims involving Paxlovid.
Market effects
Reinforces strict written-description requirements for pharma patent priority claims, potentially affecting how companies draft and prosecute continuation/provisional strategies.
US-focused patent law precedent; limited immediate regional spillover beyond US litigation risk.
May influence global pharma patent filing practices and litigation posture where priority and written description are contested.
Counterpoint
Even with this patent invalidated, Enanta may still have other asserted patents or different claim constructions that could preserve some litigation value.
Key entities
- companyEnanta Pharmaceuticals, Inc.
Plaintiff/appellant seeking to enforce U.S. Patent No. 11,358,953 against Pfizer’s Paxlovid.
- companyPfizer Inc.
Defendant/appellee arguing the patent lacked provisional priority and that intervening disclosure of nirmatrelvir was prior art.
- legal_instrumentU.S. Patent No. 11,358,953
Patent asserted as covering compounds and methods for inhibiting coronavirus replication.
- productPaxlovid (nirmatrelvir)
Pfizer’s COVID-19 therapy whose active ingredient disclosure was treated as intervening prior art.
